ZhuZhou QianJin PharmaceuticalLtd Past Earnings Performance
Past criteria checks 5/6
ZhuZhou QianJin PharmaceuticalLtd has been growing earnings at an average annual rate of 2.8%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 2.7% per year. ZhuZhou QianJin PharmaceuticalLtd's return on equity is 13%, and it has net margins of 8.4%.
Key information
2.8%
Earnings growth rate
2.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 2.7% |
| Return on equity | 13.0% |
| Net Margin | 8.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How ZhuZhou QianJin PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 3,839 | 323 | 1,169 | 186 |
| 31 Dec 23 | 3,798 | 320 | 1,184 | 149 |
| 30 Sep 23 | 3,910 | 313 | 1,166 | 143 |
| 30 Jun 23 | 4,028 | 306 | 1,181 | 123 |
| 31 Mar 23 | 4,034 | 308 | 1,180 | 113 |
| 31 Dec 22 | 4,026 | 303 | 1,174 | 114 |
| 30 Sep 22 | 3,891 | 300 | 1,152 | 107 |
| 30 Jun 22 | 3,821 | 313 | 1,136 | 101 |
| 31 Mar 22 | 3,704 | 304 | 1,112 | 107 |
| 31 Dec 21 | 3,664 | 302 | 1,127 | 109 |
| 30 Sep 21 | 3,638 | 322 | 1,132 | 112 |
| 30 Jun 21 | 3,697 | 320 | 1,182 | 113 |
| 31 Mar 21 | 3,736 | 297 | 1,196 | 113 |
| 31 Dec 20 | 3,627 | 297 | 1,111 | 104 |
| 30 Sep 20 | 3,572 | 297 | 1,118 | 119 |
| 30 Jun 20 | 3,517 | 290 | 1,095 | 106 |
| 31 Mar 20 | 3,524 | 287 | 1,079 | 104 |
| 31 Dec 19 | 3,525 | 294 | 1,122 | 105 |
| 30 Sep 19 | 3,649 | 278 | 1,181 | 90 |
| 30 Jun 19 | 3,531 | 273 | 1,154 | 87 |
| 31 Mar 19 | 3,442 | 266 | 1,193 | 90 |
| 31 Dec 18 | 3,329 | 255 | 1,145 | 84 |
| 30 Sep 18 | 3,193 | 249 | 1,167 | 79 |
| 30 Jun 18 | 3,159 | 230 | 1,055 | 125 |
| 31 Mar 18 | 3,215 | 214 | 1,082 | 92 |
| 31 Dec 17 | 3,183 | 208 | 1,083 | 79 |
| 30 Sep 17 | 3,158 | 181 | 1,056 | 57 |
| 30 Jun 17 | 3,099 | 157 | 1,199 | 0 |
| 31 Mar 17 | 3,002 | 156 | 1,163 | 0 |
| 31 Dec 16 | 2,865 | 149 | 1,075 | 0 |
| 30 Sep 16 | 2,755 | 107 | 1,112 | 0 |
| 30 Jun 16 | 2,617 | 94 | 1,039 | 0 |
| 31 Mar 16 | 2,520 | 94 | 1,023 | 0 |
| 31 Dec 15 | 2,447 | 93 | 1,006 | 0 |
| 30 Sep 15 | 2,341 | 93 | 961 | 0 |
| 30 Jun 15 | 2,276 | 102 | 942 | 0 |
| 31 Mar 15 | 2,230 | 108 | 908 | 0 |
| 31 Dec 14 | 2,194 | 105 | 892 | 0 |
| 30 Sep 14 | 2,194 | 114 | 857 | 0 |
| 30 Jun 14 | 2,139 | 117 | 827 | 0 |
| 31 Mar 14 | 2,029 | 120 | 783 | 0 |
| 31 Dec 13 | 1,973 | 124 | 776 | 0 |
| 30 Sep 13 | 1,853 | 112 | 730 | 0 |
| 30 Jun 13 | 1,755 | 104 | 699 | 0 |
Quality Earnings: 600479 has high quality earnings.
Growing Profit Margin: 600479's current net profit margins (8.4%) are higher than last year (7.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 600479's earnings have grown by 2.8% per year over the past 5 years.
Accelerating Growth: 600479's earnings growth over the past year (4.9%) exceeds its 5-year average (2.8% per year).
Earnings vs Industry: 600479 earnings growth over the past year (4.9%) exceeded the Pharmaceuticals industry -1.1%.
Return on Equity
High ROE: 600479's Return on Equity (13%) is considered low.